Enteris BioPharma Launches Contract Manufacturing within 32,000 Square Foot, FDA inspected and cGMP Compliant Facility

Enteris BioPharma Launches Contract Manufacturing
within 32,000 Square Foot, FDA inspected and cGMP Compliant Facility   

Cost-effective, high-quality production of API using microbial expression systems

Boonton, NJ – February 10, 2015Enteris BioPharma, Inc., an industry leader in oral peptide delivery, announced today the launch of contract manufacturing located within its 32,000 square foot, FDA inspected and cGMP compliant facility in Boonton, New Jersey.  

Equipped to ensure cost-effective, high-quality production of API using microbial expression systems, Enteris BioPharma offers pharmaceutical companies a full array of services to meet their manufacturing needs, from pre-clinical to commercial scale.  

Brian Zietsman, President and CFO of Enteris BioPharma, commented, "The initiation of our contract manufacturing business is an important milestone for Enteris as we seek to fully maximize the assets and expertise that we acquired when the company was launched in 2013."  

Housed within Enteris BioPharma's 32,000 square foot facility is a fully integrated manufacturing plant for producing API at multi-kilogram capacity.  The fermentation, purification and production support suite includes a 1,000 liter B. Braun microbial fermenter, 300 sq. ft. Millipore TFF membranes, an Alfa Laval disc stack centrifuge, a Rainee homogenizer, a complete downstream purification suite, multiple chromatography columns, a bulk tray lyophilizer and an explosion proof area for solvent handling and RP-HPLC.  Enteris BioPharma's manufacturing capabilities are strengthened by significant technical expertise that enables the company to offer end-to-end program support, ranging from small scale pre-clinical programs to commercial scale API manufacturing.

Paul Shields, Ph.D., Vice President, Operations of Enteris , remarked, "From fermentation to harvesting and downstream purification through to stability testing, process validation, QA and regulatory support, Enteris has the technological capability and expertise to meet a wide array of customer needs and project specifications. With the initiation of our contract manufacturing services, Enteris offers pharmaceutical partners the ability to manufacture recombinant peptide and protein products using microbial expression systems in an FDA inspected and cGMP compliant facility located in New Jersey."   

About Enteris BioPharma

Enteris BioPharma, Inc. is a privately held, New Jersey-based biotechnology company offering innovative formulation solutions built around its proprietary drug delivery technologies and contract manufacturing of recombinant peptide and protein products. Enteris' proprietary oral delivery technology has been the subject of numerous feasibility studies and active development programs, several of which are in late stage clinical development. For more information on Enteris BioPharma and its proprietary oral delivery technology and contract manufacturing capabilities, please visit http://www.EnterisBioPharma.com.

For Enteris BioPharma:

Media Contacts:

Tim Saxon

Vice President Business Development


[email protected] 

Jason Rando / Claire Sojda

Tiberend Strategic Advisors, Inc.


[email protected]

[email protected]


Suggested Articles

The FDA asked five drugmakers to pull their version of extended-release metformin off U.S. shelves after finding carcinogen contamination.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.